These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 25660156)

  • 1. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Kawakami H; Satoh T; Nakagawa K
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
    Rahman A
    Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
    Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
    Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
    Loupakis F; Schirripa M; Caparello C; Funel N; Pollina L; Vasile E; Cremolini C; Salvatore L; Morvillo M; Antoniotti C; Marmorino F; Masi G; Falcone A
    Br J Cancer; 2013 Jun; 108(12):2549-56. PubMed ID: 23703247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
    Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
    Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved first-line chemotherapy: a better chance for surgery?
    Tejpar S; Van Cutsem E; Adam R
    Lancet Oncol; 2010 Jan; 11(1):4-5. PubMed ID: 19942480
    [No Abstract]   [Full Text] [Related]  

  • 10. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
    Afonso S; Viani G; Afonso V; Stefano E; Afonso S
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
    de Melo JV; Vieira de Melo MS; Abad MH
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Cassidy J
    Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
    Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
    Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
    Sunakawa Y; Schirripa M; Lenz HJ
    Crit Rev Oncol Hematol; 2016 Apr; 100():117-26. PubMed ID: 26850575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
    Grothey A; Marshall JL
    Oncology (Williston Park); 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8. PubMed ID: 17536342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line therapy in colorectal cancer.
    Berlin J
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.